CMPS vs. ELVN, BGM, MLYS, NRIX, VIR, COLL, NTLA, RCUS, RCKT, and ZYME
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Enliven Therapeutics (ELVN), Qilian International Holding Group (BGM), Mineralys Therapeutics (MLYS), Nurix Therapeutics (NRIX), Vir Biotechnology (VIR), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), Arcus Biosciences (RCUS), Rocket Pharmaceuticals (RCKT), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry.
COMPASS Pathways vs.
Enliven Therapeutics (NASDAQ:ELVN) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.
Enliven Therapeutics is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 29.2% of Enliven Therapeutics shares are held by insiders. Comparatively, 4.3% of COMPASS Pathways shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Enliven Therapeutics' return on equity of -29.46% beat COMPASS Pathways' return on equity.
Enliven Therapeutics presently has a consensus price target of $38.75, indicating a potential upside of 80.15%. COMPASS Pathways has a consensus price target of $21.83, indicating a potential upside of 606.58%. Given COMPASS Pathways' higher probable upside, analysts plainly believe COMPASS Pathways is more favorable than Enliven Therapeutics.
COMPASS Pathways received 54 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 81.25% of users gave COMPASS Pathways an outperform vote.
Enliven Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500.
In the previous week, Enliven Therapeutics had 12 more articles in the media than COMPASS Pathways. MarketBeat recorded 13 mentions for Enliven Therapeutics and 1 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 1.87 beat Enliven Therapeutics' score of 0.97 indicating that COMPASS Pathways is being referred to more favorably in the news media.
Summary
Enliven Therapeutics beats COMPASS Pathways on 10 of the 16 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
This page (NASDAQ:CMPS) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy CMPS Stock Free CMPS Stock Alerts